The Effectiveness of Trastuzumab Combined with Sequential Chemotherapy for Metastatic Gastric Carcinoma with Overexpression of HER2
Metastatic gastric carcinoma is a mortal disease with a median survival of barely 10 months.An approximate 20% of the cases overexpress HER2, and among them, the combination of chemotherapy with trastuzumab is actually the first-line palliative treatment.However, after progression, sequential strategies of chemotherapy while DISPLAY LADDER maintain